Gemcitabine oral - INNOPHARMAX

Drug Profile

Gemcitabine oral - INNOPHARMAX

Alternative Names: D07001; D07001-F4; Gemcitabine HCl - INNOPHARMAX; Inno-D07001

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INNOPHARMAX
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 30 May 2018 Gemcitabine oral is still in phase I trials for Lymphoma and Solid tumours in Taiwan (Innopharmax pipeline, May 2018)
  • 21 May 2018 InnoPharmax plans a phase I/II trial for Gastrointestinal Cancer and Biliary-cancer in May 2018 , (NCT03531320)
  • 02 Dec 2016 Pharmacokinetics, adverse events and preliminary efficacy data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top